# Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.

> **NCT00184769** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 16 (actual)

## Conditions studied

- Chronic Kidney Disease
- Chronic Renal Insufficiency

## Interventions

- **DRUG:** somatropin

## Key facts

- **NCT ID:** NCT00184769
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-01-29
- **Primary completion:** 2005-12-21
- **Final completion:** 2005-12-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00184769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00184769, "Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00184769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*